Cancer Research Cancer Research Funding Available Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dong, J.-T.
Right arrow Articles by Frierson, H. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dong, J.-T.
Right arrow Articles by Frierson, H. F., Jr.
[Cancer Research 60, 3880-3883, July 15, 2000]
© 2000 American Association for Cancer Research

Molecular Biology and Genetics

Deletion at 13q21 Is Associated with Aggressive Prostate Cancers1

Jin-Tang Dong2, Ceshi Chen, Brian G. Stultz, John T. Isaacs and Henry F. Frierson, Jr.

Departments of Pathology [J-T. D., C. C., H. F. F.] and Biochemistry and Molecular Genetics [J-T. D., B. G. S.], University of Virginia Health System, Charlottesville, Virginia 22908, and Johns Hopkins Oncology Center, Baltimore, Maryland 21231 [J. T. I.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Previous cytogenetic and molecular genetic analyses suggest that the q21 band of chromosome 13 harbors a tumor suppressor gene(s) involved in prostatic carcinogenesis. The precise genetic location, however, has not been defined. In this study, we examined prostate cancer specimens and cell lines/xenograft for genetic deletions at 13q21, using the methods of tissue microdissection and duplex PCR. Deletions at 13q21 were detected in 13 of 147 (9%) prostate cancer samples. Deletion of the same region was also detected in the LNCaP cell line and the PC-82 xenograft of prostate cancer. The overlapping region of deletion in LNCaP and PC-82 spans 3.1 cM or 2.9 cR, which is equivalent to 1–3 Mb. The endothelin receptor B gene, a possible tumor suppressor gene at 13q21, was not located in the region of deletion. Among the 13 prostate neoplasms with deletion at 13q21, 5 were metastases, and 7 were poorly differentiated primary tumors. The only primary tumor that was not poorly differentiated but had deletion occurred in one of the youngest patients (49 years) at diagnosis. These results provide evidence that 13q21 may harbor an unidentified gene(s) whose inactivation occurs in some aggressive carcinomas of the prostate. In addition, this study provides a framework for the cloning and identification of the 13q21 gene(s).


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Molecular determinants important in the development and progression of prostate cancer are poorly understood, despite the fact that this neoplasm has become a significant health problem (1) . Cytogenetic and molecular genetic analyses have indicated that interstitial deletions on chromosomes 8p, 13q, 10q, 6q, 7q, 17q, and 18q occur frequently in human prostate cancer, suggesting the existence of tumor suppressor genes on these chromosomal arms (2, 3) . At present, however, only 10q has been identified as having a tumor suppressor gene (i.e., PTEN) that has been implicated in prostate cancer (4, 5) . The target genes from the remaining chromosomes have yet to be mapped and identified.

Deletion of portions of chromosome 13 has been detected by various genetic approaches in human prostate cancer. In a cytogenetic banding study, nonrandom loss of chromosome 13 was observed in a xenografted cell line (6) . CGH3 demonstrated that loss of 13q is the second most frequent chromosomal alteration, having occurred in 32% of primary tumors, 56–75% of recurrent and metastatic tumors, and each of the four commonly used prostate cancer cell lines derived from metastatic prostate cancer (7–11) . One CGH study suggested a deletion region at the q21 band of chromosome 13 (10) . In our LOH assay, we identified a distinct region of LOH in a 7-cM DNA segment involving markers D13S269 and D13S162 at 13q21 (12) . These studies suggested that a tumor suppressor gene is located at 13q21; however, the DNA segment containing this gene was still too large for its identification.

To fine map the region of deletion and to evaluate the clinical significance of 13q21 deletion in prostate cancer, we analyzed a number of STS markers at 13q21 for genetic deletions in prostate cancer, using the approaches of tissue microdissection and duplex PCR. The minimal region of the deletion was confined to a DNA fragment of 3.1 cM or 2.9 cR (1–3 Mb), and the deletion at 13q21 appeared to be associated with tumor aggressiveness.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Tumor Specimens, Cell Lines, and Xenograft.
A total of 147 prostate cancer tissues from 125 patients were examined for deletion in this study. Of them, 103 were primary tumors, 6 were lymph node metastases obtained at surgery, and 38 were either primary tumors (12 specimens) or metastases (26 specimens) from various organ sites obtained at autopsy from 16 patients who died of prostate cancer. Among the 103 primary tumors from surgery, one was a well-differentiated tumor (Gleason score, 4), 19 were moderately differentiated cancers (Gleason score, 5 or 6), 40 were moderately poorly differentiated tumors (Gleason score, 7), and 43 were poorly differentiated neoplasms with Gleason scores of 8–10. Each of the primary tumors from autopsy was a high-grade cancer. Patient age ranged from 42–88 years. Tumor tissues were zinc formalin-fixed and paraffin-embedded, and the cells for DNA isolation were collected from 7-µm H&E-stained sections using a previously described protocol for preparation of histological sections on glass slides before microdissection (13) , which ensured a minimum of 70% neoplastic cells. Nonneoplastic cells from lymph nodes or seminal vesicles in most of the cases or from normal prostate stroma or urothelium in the remainder of the cases were obtained from paraffin blocks that contained no neoplastic cells.

Prostate cancer cell lines LNCaP, PC-3, DU 145, and TSU-Pr1 were purchased from American Type Culture Collection (Manassas, VA) and propagated following the manufacturer’s instructions. The PC-82 prostate cancer xenograft was described previously (14) .

DNA Preparation.
For most of the tumor specimens, DNA was isolated from microdissected cells by adding proteinase K solution and incubating at 55°C overnight, followed by boiling the solution for 10 min to inactivate proteinase K, as described previously (12) . One µl of DNA sample was used in each PCR. For tumor specimens including all of the autopsy cases where greater amount of tissues were available, phenol/chloroform extraction and ethanol precipitation were performed after the proteinase K treatment. For these samples, 5–50 ng of DNA were used for each PCR. For the cell lines and the PC-82 xenograft, genomic DNA was isolated by using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI).

STS Markers.
We initially analyzed the two mapped genetic markers, i.e., D13S269 and D13S162, that are located in the 13q21 LOH region in our previous study (12) . After deletion for either of these markers was detected, additional markers that flank the deleted ones were analyzed to further define the segment with deletion. Selection of additional markers was based on the latest version of the integrated human genomic map (15) ,4 which is available on line from the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research, Human Genetic Mapping Project and from the high-resolution yeast artificial chromosome-cosmid-STS map of human chromosome 13 (16) . Primer sequences of these markers are available from the Genome Database.5 The endothelin receptor B (EDNRB) gene, which is close to but telomeric to marker D13S162 at 13q21 (17) , was also examined using a STS marker derived from its fourth exon (18) . Primer sequences for exon 4 of the EDNRB gene are 5'-ATCCCTATAGTTTTACAAGACAGC-3' (forward) and 5'-ATTTTCTTACCTGCTTTAG GTG-3' (reverse). PCR primers were either purchased from Research Genetics (Huntsville, AL) or synthesized by Life Technologies, Inc. (Gaithersburg, MD).

In addition to 13q21 markers, each PCR contained one internal control STS marker, i.e., one of the exons from the KAI1 gene whose deletion has not been found in prostate cancer (19, 20) . Internal controls were necessary for reliable detection of chromosomal deletions. Depending on the size of PCR products of a 13q21 marker, exon 5, 7, or 8 of the KAI1 gene was used. The primer sequences of these KAI1 exons have been described previously (19) . Sizes of PCR products, annealing temperatures, KAI1 control exons, genetic and physical maps, and deletion status in LNCaP and PC-82 cells for the 13q21 markers are listed in Table 1Citation .


View this table:
[in this window]
[in a new window]

  		Table 1 Genetic and radiation hybrid (RH) maps, sizes of PCR products, annealing temperatures, internal KAI1 control markers, and deletion status in LNCaP and PC-82 cells for the 13q21 markers

 
Deletion Analysis.
The duplex PCR approach was used for the deletion detection. Each PCR, which was in a volume of 10 µl, contained 1 µl of genomic DNA, 1x PCR buffer [20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.1% Triton X-100, and 0.1 mg/ml BSA], 0.4 µM of each primer, 20 µM of each deoxynucleotide triphosphate, 1 µCi of [{alpha}-33P]dATP (3000 Ci/mmol; ICN, Irvine, CA), 0.6 unit of platinum Taq antibodies (Life Technologies, Inc.), and 0.6 unit of Taq DNA polymerase. After an initial denaturation at 95°C for 5 min, 30 cycles, each consisting of denaturation at 94°C for 45 s, annealing for 45 s, and extension at 72°C for 1 min, were performed.

PCR products were separated in 5% nondenaturing polyacrylamide gels (size, 20 x 20 cm) at 200 V for 1–2 h. The gels were dried and exposed to Kodak Biomax MR film at room temperature overnight. Absence of a PCR product for a 13q21 marker in a tumor defined a deletion. However, the microdissected tumor samples were sometimes contaminated with nonneoplastic cells sufficient to give rise to PCR products. When this occurred, signal intensities for PCR products were quantitatively measured by scanning and analyzing PCR bands from a film using ScanDNASIS software (Hitachi Software, San Bruno, CA); the ratio of signal intensity of a 13q21 marker to that of the internal control marker was calculated for each DNA sample, and a deletion was considered to be present when such a ratio in a tumor was less than half of that in its matched nonneoplastic cells.

All experiments were repeated one to three times, and the deletions were detected in each of the experiments.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Based on the multiplex PCR method used for the detection of homozygous deletion in our previous study (21) , we first adjusted the experimental procedures to maximize the sensitivity and consistency in detecting genetic deletion. Compared with regular PCR and agarose gel electrophoresis, we found that the procedure of radioactive PCR with [{alpha}-33P]dATP, use of the hot-start approach by adding Taq antibodies, separation of PCR products with nondenaturing PAGE, and exposure of gels to Kodak Biomax MR film was more consistent, quantitative, and sensitive in demonstrating genetic deletions in tumor samples.

We first analyzed the two markers (i.e., D13S269 and D13S162) that were located in the LOH region at 13q21, based on our previous study (12) , in each of the 147 tumor specimens using the improved method of duplex PCR assay (Table 1)Citation . Some tumors showed absent or reduced band intensities for D13S269 and/or D13S162 compared with that of the internal control marker and with that of a normal control. We then repeated the PCR for these tumors, along with their matched nonneoplastic cells. As shown in Fig. 1Citation for some specimens, deletions at D13S269 and D13S162, which could be either homozygous deletions or hemizygous deletions, were repeatedly detected in 13 tumor specimens. Whereas 11 of 13 tumors lost both D13S269 and D13S162, 2 tumors lost D13S269 only (Table 2Citation ).



View larger version (37K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Detection of deletion at 13q21 in prostate cancer by duplex PCR assay. Case number and tissue type are indicated at the top, STS markers are indicated at the left, and the size of the PCR products is indicated at the right. Each arrow denotes a deletion at a marker in a neoplasm. Lanes P and M, primary tumor and metastasis obtained from autopsy specimens; Lane T, primary tumor obtained at surgery; Lane N, matched nonneoplastic cells in each case. Due to the polymorphic feature of microsatellite markers, two bands that represent two alleles are seen for both markers in most cases. Case 42 (Lane P ) appears to have LOH instead of deletion at D13S162.

 

View this table:
[in this window]
[in a new window]

  		Table 2 Prostate cancers showing deletions at D13S269 and D13S162 and patient age at diagnosis and Gleason score (G.S.). "M" indicates a metastasis

Presence or absence of a marker in a tumor is indicated by + or -, respectively.

 
In total, 13 of 147 (9%) prostate cancer samples showed deletion at 13q21. Patient age at diagnosis and Gleason score for these neoplasms are shown in Table 2Citation . Among these tumors, five were metastases, and seven were poorly differentiated primary tumors. The only primary tumor that was not poorly differentiated but had a deletion (case 233) occurred in one of the youngest patients (49 years) at diagnosis.

To determine whether deletion at 13q21 also occurred in prostate cancer cell lines and xenograft, we analyzed D13S269 and D13S162 for deletion using the same duplex PCR method. As shown in Table 1Citation and Fig. 2Citation , whereas three cell lines did not show any deletions, the LNCaP cell line and the PC-82 xenograft showed a significant signal reduction at D13S269 and D13S162. Measurement of signal intensities using the ScanDNASIS program indicated that the signal ratio of the deleted marker to the internal control in LNCaP cells was only about one-fourth of that in the normal placenta control DNA. Deletion analysis of cell lines and xenograft was also repeated using regular PCR and agarose gel electrophoresis, and deletion of D13S269 and D13S162 was demonstrated in each experiment (data not shown).



View larger version (38K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Deletions of 13q21 markers in LNCaP cell line and PC-82 xenograft of prostate cancer. Sample names are indicated at the top, and marker names are indicated at the left. Markers deleted are indicated by vertical bars at the right. Normal DNA was from a normal human placenta.

 
To determine the size of the region with deletion, we selected more STS markers (Table 1)Citation that flank D13S269 and/or D13S162 at 13q21 and examined them in LNCaP and PC-82 tumor cells that showed deletions at D13S269 and D13S162 and had a sufficient quantity of pure tumor DNA for analysis (Table 1Citation ; Fig. 2Citation ). The deletion region in LNCaP was different from but overlapped that in PC-82, and the common region of deletion was defined as a DNA segment of 3.1 cM within markers D13S1090E and BS610/611 or 2.9 cR within markers WI-5860 and BS610/611 (Table 1)Citation . According to the current genomic maps (15, 16) , the size of this common region of deletion was estimated to be 1–3 Mb. The endothelin receptor B (EDNRB) gene, which is located at least 3 cM telomeric to the common region of deletion at 13q21 and has been suggested as a tumor suppressor gene, was also analyzed in five tumors and in all of the cell lines but showed no deletion (data not shown).


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this study, we first improved the multiplex PCR procedure used in our previous study (21) for the detection of genetic deletion in human tumors. Use of radioactive PCR with a hot-start approach, PAGE, and exposure to Kodak Biomax MR film made deletion detection more reliable when compared with regular PCR and agarose gel electrophoresis. As shown in Fig. 1Citation , some tumor samples had no signal or a very faint signal at the deleted markers D13S269 and D13S162 compared with their matched nonneoplastic cells. Detection of deletion in the LNCaP cell line but not in any other cell lines further indicated the feasibility of our methods because a high-resolution cytogenetic banding study showed that each LNCaP cell has an interstitial deletion at 13q21 in some but not all of its copies of chromosome 13 [it has a near tetraploid karyotype (22) ].

Genetic deletion at 13q21 in prostate cancer was first demonstrated by a cytogenetic banding study in the LNCaP cell line (22) . In CGH analyses, deletion of 13q was detected in human prostate cancer tissues and in each of the four commonly used prostate cancer cell lines (7–11) , and a common region of deletion was suggested to be located at 13q21 (10) . Recently, our LOH study further showed that the deletion at 13q21 involved markers D13S313, D13S269, D13S162, and D13S1306 in a DNA interval of 7 cM (12) . Using the methods of tissue microdissection and an improved duplex PCR assay, we found that genetic deletions at 13q21 occurred in 13 of 147 (9%) prostate cancer specimens and 2 of 5 (40%) prostate cancer cell lines and xenograft. Consistent with previous studies, our data provide additional evidence for the existence of a tumor suppressor gene(s) at 13q21.

Although previous studies identified a region of deletion at 13q21 in prostate cancer, the size of the region with deletion was still too large for gene identification, and the precise location of the target gene remained to be defined. Using densely mapped genetic markers and the LNCaP cell line and PC-82 xenograft of prostate cancer, we defined the common region of deletion to be in a 3.1-cM segment within markers D13S1090E and BS610/611 and a 2.9-cR segment between WI-5860 and BS610/611 (Table 1)Citation . Considering that, on average, 1 cM is equivalent to 1 Mb and 1 Mb is equivalent to 3.7 cR for the Genebridge4 Radiation Hybrid Panel,6 our findings indicate that the minimal region of deletion containing the target gene should be in the size range of 1–3 Mb.

Twelve of the 13 prostate cancer samples with homozygous deletion at 13q21 were either poorly differentiated primary tumors or metastases. The only primary tumor that was not poorly differentiated but had a deletion occurred in one of the youngest patients (49 years) at diagnosis (Table 2)Citation . The LNCaP cell line and the PC-82 xenograft, which were noted above to have a deletion at the same region of 13q21, were also derived from metastases of prostate cancer (23) . These data indicate that deletion at 13q21 occurs in biologically aggressive prostate cancers. Consistently, a previous study found that patients whose prostate cancers showed LOH at 13q were diagnosed at a significantly younger age than those whose tumors lacked LOH at 13q (12) .

The endothelin receptor B (EDNRB) gene is located at 13q21, telomeric to marker D13S162 but centromeric to marker D13S160 (17) . Considering that promoter methylation of the EDNRB gene occurs frequently in prostate cancer and that this gene has been suggested to act as a tumor suppressor (24) , we analyzed its deletion status in five tumors that showed deletion at D13S269 and D13S162 and in all of the prostate cancer cell lines. No deletion at the EDNRB gene was detected. Based on the current genomic map, EDNRB is at least 3 cM telomeric to the common region of deletion. Therefore, EDNRB is not the target gene for the 13q21 deletion region in prostate cancer. Currently, there is no gene that is located in the region of deletion that has been identified as a tumor suppressor. This study provides a framework for the identification of this gene.

Genetic deletion involving 13q21 has also been detected by CGH in malignant fibrous histiocytomas (25, 26) and other sarcomas (27, 28) , and gliomas (29, 30) . These studies suggest that different types of tumors may share the same genetic alteration at 13q21 during carcinogenesis or progression.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by Grant DAMD 17-98-1-8636 from the United States Army Prostate Cancer Research Program and by NIH Grant 1 R01 CA87921 from the National Cancer Institute. Back

2 To whom requests for reprints should be addressed, at Department of Pathology, University of Virginia Health System, P. O. Box 800214, Charlottesville, VA 22908-0214. Phone: (804) 924-9011; Fax: (804) 924-9206; E-mail: jd4q{at}virginia.edu Back

3 The abbreviations used are: CGH, comparative genomic hybridization; LOH, loss of heterozygosity; STS, sequence tagged site. Back

4 Supplementary data from the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research, Human Genetic Mapping Project (http://www-genome.wi.mit.edu). Back

5 http://gdbwww.gdb.org. Back

6 http://carbon.wi.mit.edu:8000/ftp/distribution/human_STS_releases/july97/07-97.INTRO.html. Back

Received 12/ 8/99. Accepted 5/10/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Landis S. H., Murray T., Bolden S., Wingo P. A. Cancer statistics, 1999. CA Cancer J. Clin, 49: 8-31, 1999.[Abstract/Free Full Text]
  2. Isaacs W. B., Bova G. S. Prostate cancer Vogelstein B. Kinzler K. W. eds. . The Genetic Basis of Human Cancer, : 653-660, McGraw-Hill, Inc. New York 1997.
  3. Brothman A. R., Maxwell T. M., Cui J., Deubler D. A., Zhu X. L. Chromosomal clues to the development of prostate tumors. Prostate, 38: 303-312, 1999.[Medline]
  4. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S. H., Giovanella B. C., Ittmann M., Tycko B., Hibshoosh H., Wigler M. H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Washington DC), 275: 1943-1947, 1997.[Abstract/Free Full Text]
  5. Vlietstra R. J., van Alewijk D. C., Hermans K. G., van Steenbrugge G. J., Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res, 58: 2720-2723, 1998.[Abstract/Free Full Text]
  6. Pittman S., Russell P. J., Jelbart M. E., Wass J., Raghavan D. Flow cytometric and karyotypic analysis of a primary small cell carcinoma of the prostate: a xenografted cell line. Cancer Genet. Cytogenet, 26: 165-169, 1987.[Medline]
  7. Cher M. L., MacGrogan D., Bookstein R., Brown J. A., Jenkins R. B., Jensen R. H. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer, 11: 153-162, 1994.[Medline]
  8. Cher M. L., Bova G. S., Moore D. H., Small E. J., Carroll P. R., Pin S. S., Epstein J. I., Isaacs W. B., Jensen R. H. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res, 56: 3091-3102, 1996.[Abstract/Free Full Text]
  9. Visakorpi T., Kallioniemi A. H., Syvanen A. C., Hyytinen E. R., Karhu R., Tammela T., Isola J. J., Kallioniemi O. P. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res, 55: 342-347, 1995.[Abstract/Free Full Text]
  10. Nupponen N. N., Hyytinen E. R., Kallioniemi A. H., Visakorpi T. Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet. Cytogenet, 101: 53-57, 1998.[Medline]
  11. Nupponen N. N., Kakkola L., Koivisto P., Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am. J. Pathol, 153: 141-148, 1998.[Abstract/Free Full Text]
  12. Hyytinen E. R., Frierson H. F., Boyd J. C., Chung L. W. K., Dong J. T. Three distinct regions of allelic loss at 13q14, 13q21–22, and 13q33 in prostate cancer. Genes Chromosomes Cancer, 25: 108-114, 1999.[Medline]
  13. Moskaluk C. A., Kern S. E. Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. Am. J. Pathol, 150: 1547-1552, 1997.[Abstract]
  14. Gao J., Isaacs J. T. Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells. Cancer Res, 58: 3299-3306, 1998.[Abstract/Free Full Text]
  15. Hudson T. J., Stein L. D., Gerety S. S., Ma J., Castle A. B., Silva J., Slonim D. K., Baptista R., Kruglyak L., Xu S. H., Hu X., Colbert A. M. E., Rosenberg C., Reeve-Daly M. P., Rozen S., Hui L., Wu X., Vestergaard C., Wilson K. M., Bae J. S., Maitra S., Ganiatsas S., Evans C. A., DeAngelis M. M., Ingalls K. A., Nahf R. W., Horton L. T., Anderson M. O., Collymore A. J., Ye W., Kouyoumjian V., Zemsteva I. S., Tam J., Devine R., Courtney D. F., Renaud T. M., Nguyen H., O’Connor T. J., Fizames C., Faure S., Gyapay G., Dib C., Morissette J., Orlin J. B., Birren B. W., Goodman N., Weissenbach J., Hawkins T. L., Foote S., Page D. C., Lander E. S. An STS-based map of the human genome. Science (Washington DC), 270: 1945-1954, 1995.[Abstract]
  16. Cayanis E., Russo J. J., Kalachikov S., Ye X., Park S. H., Sunjevaric I., Bonaldo M. F., Lawton L., Venkatraj V. S., Schon E., Soares M. B., Rothstein R., Warburton D., Edelman I. S., Zhang P., Efstratiadis A., Fischer S. G. High-resolution YAC-cosmid-STS map of human chromosome 13. Genomics, 47: 26-43, 1998.[Medline]
  17. Deloukas P., Schuler G. D., Gyapay G., Beasley E. M., Soderlund C., Rodriguez-Tome P., Hui L., Matise T. C., McKusick K. B., Beckmann J. S., Bentolila S., Bihoreau M., Birren B. B., Browne J., Butler A., Castle A. B., Chiannilkulchai N., Clee C., Day P. J., Dehejia A., Dibling T., Drouot N., Duprat S., Fizames C., Fox S., Gelling S., Green L., Harrison P., Hocking R., Holloway E., Hunt S., Keil S., Lijnzaad P., Louis-Dit-Sully C., Ma J., Mendis A., Miller J., Morissette J., Muselet D., Nusbaum H. C., Peck A., Rozen S., Simon D., Slonim D. K., Staples R., Stein L. D., Stewart E. A., Suchard M. A., Thangarajah T., Vega-Czarny N., Webber C., Wu X., Hudson J., Auffray C., Nomura N., Sikela J. M., Polymeropoulos M. H., James M. R., Lander E. S., Hudson T. J., Myers R. M., Cox D. R., Weissenbach J., Boguski M. S., Bentley D. R. A physical map of 30,000 human genes. Science (Washington DC), 282: 744-746, 1998.[Abstract/Free Full Text]
  18. Puffenberger E. G., Hosoda K., Washington S. S., Nakao K., deWit D., Yanagisawa M., Chakravart A. A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung’s disease. Cell, 79: 1257-1266, 1994.[Medline]
  19. Dong J. T., Isaacs W. B., Barrett J. C., Isaacs J. T. Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics, 41: 25-32, 1997.[Medline]
  20. Dong J. T., Suzuki H., Pin S. S., Bova G. S., Schalken J. A., Isaacs W. B., Barrett J. C., Isaacs J. T. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res, 56: 4387-4390, 1996.[Abstract/Free Full Text]
  21. Dong J. T., Sipe T. W., Hyytinen E. R., Li C. L., Heise C., McClintock D. E., Grant C. D., Chung L. W., Frierson H. F., Jr. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene, 17: 1979-1982, 1998.[Medline]
  22. Gibas Z., Becher R., Kawinski E., Horoszewicz J., Sandberg A. A. A high-resolution study of chromosome changes in a human prostatic carcinoma cell line (LNCaP). Cancer Genet. Cytogenet, 11: 399-404, 1984.[Medline]
  23. Horoszewicz J. S., Leong S. S., Chu T. M., Wajsman Z. L., Friedman M., Papsidero L., Kim U., Chai L. S., Kakati S., Arya S. K., Sandberg A. A. The LNCaP cell line: a new model for studies on human prostatic carcinoma Murphy G. P. eds. . Models for Prostate Cancer, : 115-132, Alan R, Liss, Inc. New York 1980.
  24. Nelson J. B., Lee W. H., Nguyen S. H., Jarrard D. F., Brooks J. D., Magnuson S. R., Opgenorth T. J., Nelson W. G., Bova G. S. Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res, 57: 35-37, 1997.[Abstract/Free Full Text]
  25. Larramendy M. L., Tarkkanen M., Blomqvist C., Virolainen M., Wiklund T., Asko-Seljavaara S., Elomaa I., Knuutila S. Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker. Am. J. Pathol, 151: 1153-1161, 1997.[Abstract]
  26. Mairal A., Terrier P., Chibon F., Sastre X., Lecesne A., Aurias A. Loss of chromosome 13 is the most frequent genomic imbalance in malignant fibrous histiocytomas. A comparative genomic hybridization analysis of a series of 30 cases. Cancer Genet. Cytogenet, 111: 134-138, 1999.[Medline]
  27. Szymanska J., Tarkkanen M., Wiklund T., Virolainen M., Blomqvist C., Asko-Seljavaara S., Tukiainen E., Elomaa I., Knuutila S. Gains and losses of DNA sequences in liposarcomas evaluated by comparative genomic hybridization. Genes Chromosomes Cancer, 15: 89-94, 1996.[Medline]
  28. Szymanska J., Serra M., Skytting B., Larsson O., Virolainen M., Akerman M., Tarkkanen M., Huuhtanen R., Picci P., Bacchini P., Asko-Seljavaara S., Elomaa I., Knuutila S. Genetic imbalances in 67 synovial sarcomas evaluated by comparative genomic hybridization. Genes Chromosomes Cancer, 23: 213-219, 1998.[Medline]
  29. Kim D. H., Mohapatra G., Bollen A., Waldman F. M., Feuerstein B. G. Chromosomal abnormalities in glioblastoma multiforme tumors and glioma cell lines detected by comparative genomic hybridization. Int. J. Cancer, 60: 812-819, 1995.[Medline]
  30. Nishizaki T., Ozaki S., Harada K., Ito H., Arai H., Beppu T., Sasaki K. Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization. Genes Chromosomes Cancer, 21: 340-346, 1998.[Medline]



This article has been cited by other articles:


Home page
 BloodHome page
D. Ng, O. Toure, M.-H. Wei, D. C. Arthur, F. Abbasi, L. Fontaine, G. E. Marti, J. F. Fraumeni Jr, L. R. Goldin, N. Caporaso, et al.
Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia
Blood, February 1, 2007; 109(3): 916 - 925.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X.-Y. Dong, C. Chen, X. Sun, P. Guo, R. L. Vessella, R.-X. Wang, L. W.K. Chung, W. Zhou, and J.-T. Dong
FOXO1A Is a Candidate for the 13q14 Tumor Suppressor Gene Inhibiting Androgen Receptor Signaling in Prostate Cancer.
Cancer Res., July 15, 2006; 66(14): 6998 - 7006.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. von Knobloch, L. Konrad, P. J. Barth, H. Brandt, S. Wille, A. Heidenreich, R. Moll, and R. Hofmann
Genetic Pathways and New Progression Markers for Prostate Cancer Suggested by Microsatellite Allelotyping
Clin. Cancer Res., February 1, 2004; 10(3): 1064 - 1073.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
W. G. Nelson, A. M. De Marzo, and W. B. Isaacs
Prostate Cancer
N. Engl. J. Med., July 24, 2003; 349(4): 366 - 381.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. Chen, E.-R. Hyytinen, X. Sun, H. J. Helin, P. A. Koivisto, H. F. Frierson Jr, R. L. Vessella, and J.-T. Dong
Deletion, Mutation, and Loss of Expression of KLF6 in Human Prostate Cancer
Am. J. Pathol., April 1, 2003; 162(4): 1349 - 1354.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dong, J.-T.
Right arrow Articles by Frierson, H. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dong, J.-T.
Right arrow Articles by Frierson, H. F., Jr.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online